UBS Group’s Tarsus Pharmaceuticals TARS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.15M | Sell |
28,506
-64,181
| -69% | -$2.6M | ﹤0.01% | 4244 |
|
|
2025
Q1 | $4.76M | Buy |
92,687
+31,380
| +51% | +$1.61M | ﹤0.01% | 2991 |
|
|
2024
Q4 | $3.39M | Sell |
61,307
-8,009
| -12% | -$443K | ﹤0.01% | 3293 |
|
|
2024
Q3 | $2.28M | Buy |
69,316
+41,343
| +148% | +$1.36M | ﹤0.01% | 2924 |
|
|
2024
Q2 | $760K | Sell |
27,973
-10,367
| -27% | -$282K | ﹤0.01% | 3622 |
|
|
2024
Q1 | $1.39M | Buy |
38,340
+7,847
| +26% | +$285K | ﹤0.01% | 3300 |
|
|
2023
Q4 | $617K | Buy |
30,493
+11,492
| +60% | +$233K | ﹤0.01% | 3817 |
|
|
2023
Q3 | $338K | Buy |
19,001
+1,539
| +9% | +$27.3K | ﹤0.01% | 3886 |
|
|
2023
Q2 | $316K | Buy |
17,462
+9,405
| +117% | +$170K | ﹤0.01% | 4160 |
|
|
2023
Q1 | $101K | Buy |
8,057
+1,199
| +17% | +$15.1K | ﹤0.01% | 4833 |
|
|
2022
Q4 | $101K | Buy |
6,858
+6,158
| +880% | +$90.3K | ﹤0.01% | 4978 |
|
|
2022
Q3 | $12K | Hold |
700
| – | – | ﹤0.01% | 7081 |
|
|
2022
Q2 | $10K | Sell |
700
-3,526
| -83% | -$50.4K | ﹤0.01% | 6965 |
|
|
2022
Q1 | $71K | Buy |
4,226
+1,142
| +37% | +$19.2K | ﹤0.01% | 5152 |
|
|
2021
Q4 | $70K | Buy |
3,084
+2,584
| +517% | +$58.7K | ﹤0.01% | 5538 |
|
|
2021
Q3 | $11K | Buy |
+500
| New | +$11K | ﹤0.01% | 6762 |
|
|
2021
Q2 | – | Sell |
-2,496
| Closed | -$80K | – | 8586 |
|
|
2021
Q1 | $80K | Buy |
2,496
+1,171
| +88% | +$37.5K | ﹤0.01% | 5143 |
|
|
2020
Q4 | $55K | Buy |
+1,325
| New | +$55K | ﹤0.01% | 5111 |
|